Parenteral Drugs (India) Limited (PDPL) Income Statement
Parenteral Drugs (India) Limited Income Statement
Last quarter (Q4 2022), Parenteral Drugs (India) Limited's total revenue was $17.73M, an increase of 143.66% from the same quarter last year. In Q4, Parenteral Drugs (India) Limited's net income was $238.13M. See Parenteral Drugs (India) Limited’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 |
|---|---|---|---|---|---|
| $ 84.96M | $ 121.53M | $ 240.25M | $ 319.98M | $ 2.17B | |
| $ 30.31M | $ 48.37M | $ 13.40M | $ 75.64M | $ 370.93M | |
| $ 147.87M | $ 356.03M | $ 329.28M | $ 943.42M | $ 796.06M | |
| Depreciation and Amortization | $ 401.48M | $ 173.26M | $ 173.46M | $ 691.19M | $ 242.43M |
| $ 372.69M | $ -117.09M | $ -144.39M | $ -162.40M | $ -12.93M | |
| $ -117.56K | $ -82.97K | $ -320.32K | $ -867.78K | $ -425.13M | |
| $ -973.70K | $ -1.46M | $ -1.42B | $ -946.19M | $ -987.37M | |
| $ -1.09M | $ -1.54M | $ -1.42B | $ -1.81B | $ -1.41B | |
| $ -763.62M | $ -1.22B | $ -1.14B | $ -1.48B | $ -1.19B | |
| Per Share Metrics | |||||
| Basic EPS | $ -25.61 | $ -40.82 | $ -38.26 | $ -49.61 | $ -39.89 |
| Diluted EPS | $ -25.61 | $ -40.82 | $ -38.26 | $ -49.61 | $ -39.89 |
| Weighted Average Shares Outstanding | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M |
| Weighted Average Shares Outstanding (Diluted) | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M |
Currency in INR